Hepatocellular Carcinoma News and Research

RSS

Hepatocellular Carcinoma is a type of adenocarcinoma, the most common type of liver tumor.

Study reveals possibility to selectively target and block crucial microRNA in liver cancer

A new study shows that it is possible to selectively target and block a particular microRNA that is important in liver cancer. The findings might offer a new therapy for this malignancy, which kills an estimated 549,000 people worldwide annually.

4 Jan 2012

Two new studies offer clearer picture of rise of hepatocellular carcinoma

Doctors have known for years that the incidence of deadly liver cancer is on the rise, but what is causing that trend has remained a mystery. Two recent Mayo Clinic studies published in the January issue of Mayo Clinic Proceedings offer a clearer picture of the rise of hepatocellular carcinoma (HCC), or liver cancer, which has tripled in the U.S. in the last three decades and has a 10 to 12 percent five-year survival rate when detected in later stages.

4 Jan 2012

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Can-Fite BioPharma Ltd, a biotechnology company developing small molecule drugs for the treatment of inflammatory, and liver diseases, traded on the Tel Aviv Stock Exchange announced today the successful results of the Phase 1/2 study of its drug candidate CF102 in the treatment of hepatocellular carcinoma.

4 Jan 2012

Scientists discover mechanism by which TNFα stimulates tumor formation

An inflammation-promoting protein triggers deactivation of a tumor-suppressor that usually blocks cancer formation via the NOTCH signaling pathway, a team of researchers led by scientists at The University of Texas MD Anderson Cancer Center reports today in Molecular Cell.

23 Dec 2011

Liver transplantations for NASH-Cirrhosis increase dramatically

Nonalcoholic steatohepatitis (NASH) occurs when fat builds up in the liver. This accumulation of fat damages the liver and leads to cirrhosis. NASH is rapidly increasing in the U.S. mainly related to the epidemics of obesity and diabetes.

15 Dec 2011

Two studies uncover limitations in screening for hepatocellular carcinoma

Two studies available in the December issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, have uncovered limitations in screening for primary liver cancer, also known as hepatocellular carcinoma.

2 Dec 2011

EGCG may prevent HCV reinfection after liver transplantation

German researchers have determined that epigallocatechin-3-gallate (EGCG)—a flavonoid found in green tea—inhibits the hepatitis C virus (HCV) from entering liver cells.

1 Dec 2011

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Mirna Therapeutics, Inc., a biotechnology company pioneering microRNA replacement therapy for cancer, announced the presentation today of new preclinical data on the development of a miRNA-based therapeutic candidate for primary liver cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, CA.

16 Nov 2011

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced that data and study design features on PV-10 for metastatic melanoma were presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting, in Tampa, Florida.

14 Nov 2011

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces that data from its Phase 2 PV-10 metastatic melanoma study will be presented at the 2011 International Melanoma Congress on November 12, 2011, during the 5th Meeting of Interdisciplinary Melanoma/Skin Cancer Centres meeting.

11 Nov 2011

New studies could fundamentally change medical treatment of liver cancer

Scientists at the Helmholtz Zentrum München have played a major role in two studies that could fundamentally change the medical treatment of liver cancer. Doctors are now able to determine the degree of aggressiveness of the tumour in the early stages and can thus devise an individualised treatment plan.

10 Nov 2011

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic virus products for cancer, together with its international commercialization partners, today announced that enrollment has been initiated and the first patient has been randomized in a Phase 2b clinical trial called TRAVERSE.

4 Nov 2011

Common risk factors for hepatocellular cancer

Among known risk factors for hepatocellular cancer, smoking, obesity, and heavy alcohol consumption, along with chronic hepatitis B and C infection, contribute to a large share of the disease burden in Europe, according to a cohort study published online October 21 in the Journal of the National Cancer Institute.

22 Oct 2011

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

4SC AG, a discovery and development company of targeted small molecule drugs for autoimmune diseases and cancer, today announced that the European Medicines Agency (EMA) has recommended 4SC's anti-cancer compound resminostat for designation as orphan medicinal product for the treatment of Hodgkin's Lymphoma (HL), a cancer of the lymphatic system.

13 Oct 2011

Scripps Research receives NIH grant to determine how HCV induces liver cancer

The Scripps Research Institute has been awarded a $2.2 million grant by the National Institutes of Health (NIH) to determine how the hepatitis C virus (HCV) induces liver cancer.

11 Oct 2011

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Bristol-Myers Squibb Company announced today that 22 abstracts on the Company's research in liver disease have been accepted for presentation at The Liver Meeting 2011, the 62nd annual meeting of the American Association for the Study of Liver Diseases, in San Francisco, November 4 - 8.

1 Oct 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Patients with non-alcoholic fatty liver disease (NAFLD) with advanced fibrosis or cirrhosis have a lower incidence of liver-related complications and hepatocellular carcinoma (HCC) than patients infected with hepatitis C virus (HCV), according to the prospective study published in the October issue of Hepatology, a journal of the American Association for the Study of Liver Diseases.

28 Sep 2011

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

New research shows liver transplantation candidates without hepatocellular carcinoma (HCC) derive a greater survival benefit from a living donor liver transplant (LDLT) than waiting for a deceased donor liver transplant.

28 Sep 2011

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

Boehringer Ingelheim's investigational tyrosine kinase inhibitor (TKI) BIBF 1120 demonstrated a positive trend in reducing lung function decline in patients with idiopathic pulmonary fibrosis (IPF), according to phase II clinical trial results published today online in the New England Journal of Medicine.

22 Sep 2011

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Bayer HealthCare announced today that the company will present data on several of its investigational compounds at the 2011 European Multidisciplinary Cancer Congress (ECCO-ESMO), September 23-27, 2011, in Stockholm, Sweden.

13 Sep 2011

Hepatocellular Carcinoma News and Research

Further Reading

Study reveals possibility to selectively target and block crucial microRNA in liver cancer

Two new studies offer clearer picture of rise of hepatocellular carcinoma

Positive results from Can-Fite BioPharma's CF102 Phase 1/2 study on HCC

Scientists discover mechanism by which TNFα stimulates tumor formation

Liver transplantations for NASH-Cirrhosis increase dramatically

Two studies uncover limitations in screening for hepatocellular carcinoma

EGCG may prevent HCV reinfection after liver transplantation

Mirna reports new preclinical data of miRNA-based therapeutic candidate for hepatocellular carcinoma

Provectus presents data from PV-10 Phase 2 study at 2011 International Melanoma Congress

Provectus announces data from Phase 2 PV-10 metastatic melanoma study

New studies could fundamentally change medical treatment of liver cancer

Jennerex commences enrollment in JX-594 Phase 2b trial for HCC

Common risk factors for hepatocellular cancer

EMA recommends 4SC's resminostat for orphan medicinal product designation to treat HL

Scripps Research receives NIH grant to determine how HCV induces liver cancer

Bristol-Myers to present abstracts on research in liver disease at The Liver Meeting 2011

Long-term morbidity and mortality of NAFLD patients with advanced fibrosis, cirrhosis

Liver transplantation candidates without HCC derive greater survival benefit from LDLT

NEJM publishes Boehringer Ingelheim's BIBF 1120 phase II trial on IPF

New data from Bayer's investigational oncology compounds to be presented at ECCO-ESMO congress

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News